Supriya Lifescience Limited · NSE:SUPRIYA
Supriya Lifescience — Q1 FY27 Earnings Presentation
31 slides from Supriya Lifescience's earnings presentation, Aug 13, 2026
Slide 1: Letter to stock exchanges: Investor Presentation
August 13, 2026 To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, Dalal Street, Bandra-Kurla Complex Mumbai- 400 001 Bandra (E), Mumbai - 400 051 Scrip Code: 543434 NSE Symbol: SUPRIYA Dear Sir/Madam, Subject: Investor Presenta
Slide 2: Q1 FY27 Investor Presentation
SUPRIYA LIFESCIENCE LTD. SUPRIYA LIFESCIENCE LTD. Q1 FY27 Investor Presentation
Slide 3: Safe Harbour
Safe Harbour SUPRIYA LIFESCIENCE LTD. This presentation and the accompanying slides (the “Presentation”), which have been prepared by Supriya Lifescience Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purch
Slide 4: Q1 FY27 Highlights
Q1 FY27 Highlights SUPRIYA LIFESCIENCE LTD.
Slide 5: Q1 FY27 Highlights: Regional Performance
Q1 FY27 Highlights SUPRIYA LIFESCIENCE LTD. Revenue EBITDA PBT PAT Quarterly INR 1,897.5 Mn INR 474.6 Mn INR 407.9 Mn INR 240.4 Mn 31% YoY 8% YoY 14% YoY 31% YoY Business Mix Revenue Contribution – By Region Regional Performance 44% 39% 41% 32% 34% 35% ■ Q1 FY26 20% Q4 FY26 17% 17% ■ 6% ■ Q1 FY27 4%
Slide 6: Q1 FY27 Y-o-Y Highlights
Q1 FY27 Y-o-Y Highlights SUPRIYA LIFESCIENCE LTD. (INR Mn) Revenue EBITDA PBT PAT 31% YoY 8% YoY 14% YoY 31% YoY 1897.5 474.1 347.9 1450.7 517.0 240.4 474.6 407.9 Q1FY26 Q1FY27 Q1FY26 Q1FY27 Q1FY26 Q1FY27 Q1FY26 Q1FY27 EBITDA Margins PAT Margins 1,063 bps YoY 1,131 bps YoY 35.6% 24.0% 25.0% 12.7% Q1
Slide 7: Business Mix Revenue Contribution – By Therapy
Business Mix Revenue Contribution – By Therapy SUPRIYA LIFESCIENCE LTD. Performance of the Top Therapeutic Areas 53% 48% 17% 13% 11% 9% 9% 6% 5% 4% -- - -- 3% 3% 3% 2% Anesthetic Analgesic Anti-Histamine Vitamins Anti-Asthmatic Anti-Allergic Anti-hypertensive ■ Q1FY26 ■ Q1FY27 6
Slide 8: Profit & Loss Statement
Profit & Loss Statement SUPRIYA LIFESCIENCE LTD. Particulars (in INR Mn) Q1 FY27 Q1 FY26 Y-o-Y Q4 FY26 Q-o-Q Revenue from Operations 1,897.5 1450.7 30.8% 2,765.3 -31.4% t Cost of Goods Sold 563.9 317.7 77.5% 1053.3 -46.5% t Employee Benefits Expense 284.9 226.9 25.6% 248.2 14.8% t Other Expenses 574
Slide 9: Company Overview
Company Overview SUPRIYA LIFESCIENCE LTD.
Slide 10: Business Overview
Business Overview SUPRIYA LIFESCIENCE LTD. Global leader in Anti-histamines, Anti-Allergic, Vitamins, Anti-Asthamatics & Anesthetics 40+ APIs 120+ Countries 35,000 Sq.mts 932 KLPD Niche product basket Diversified operations with presence Manufacturing facility spread across Reactor capacity WHO-GMP,
Slide 11: Journey So Far
Journey So Far SUPRIYA LIFESCIENCE LTD. 2022 2023 2024 2025 2026 • • • CEP (Certificate of The Company commenced ANVISA Approval Launch of three Commercialized CMO suitability ) renewed for operations at its Granted molecules including facility at Ambernath Pheniramine Maleate, new R&D lab in Liquid
Slide 12: Backward Integrated Business Model
Backward Integrated Business Model SUPRIYA LIFESCIENCE LTD. + + Cost-competitive Supply Security Low Price Risk In-House Processes Structure Steady supply of essential raw Protection against market Less Dependence On External Increasing margins materials fluctuations Parties 20 products are backward
Slide 13: Diversified Geographic Presence
~ SUPRIYA Diversified Geographic Presence ~ LIFESCIENCE LTD. FY26 Product Updates Cardio Vascular A key product was launched in Q3FY26, revenue contribution started in Q4FY26, with momentum strengthening for future scale-up. -\ Ji tl ~----- t,' t~.. ' I ~ ~. l~ ADHD A key product was launched, it sa
Slide 14: Diversified Revenues with Extensive Global Presence
Diversified Revenues with Extensive Global Presence SUPRIYA LIFESCIENCE LTD. Significant export presence, with low dependence on a … with balanced customer concentration specific geography Export sales, as a % of revenue from operations Share of top 10 customers, as a % of revenue from operations 85
Slide 15: Advanced Manufacturing
~ SUPRIYA Advanced Manufacturing ~ LIFESCIENCE LTD. o Well defined areas for R&D, Quality Control (chemical, microbiology), Quality Assurance, dedicated areas for engineering maintenance, i 55 9 warehouse, raw materials, packaging materials and I I Manufacturing Blocks Clean Rooms I finished goods s
Slide 16: Ambernath Facility
Ambernath Facility SUPRIYA LIFESCIENCE LTD. Facility Location R&D Manufacturing • The site spans 5,000 sqm, with 70% of the area • Dosage forms R&D being set up for tablets, capsules, • FDF facilities commissioned. constructed, located at Plot No. N-60, liquids, sterile forms. • Tablets, capsules, l
Slide 17: R&D Capabilities
R&D Capabilities SUPRIYA LIFESCIENCE LTD. Supported by R&D driven mindset DSIR approved facility • A team of 68+ scientists primarily focused on API and formulations process development across the value chain • Already started two R&D centres – 4* Process Patent o Ambernath R&D – Formulations and Ge
Slide 18: CMO Capabilities
CMO Capabilities SUPRIYA LIFESCIENCE LTD. • State-of-the-art, GMP compliant manufacturing facility along with pilot facility for scale up available for trials before validation • Complete support in validation, stability, & compilation of dossiers • Dedicated technology transfer team is periodically
Slide 19: Complex Chemistries & Reaction (1/2)
Complex Chemistries & Reaction (1/2) SUPRIYA LIFESCIENCE LTD. Focus on uniform manufacturing standards to achieve standardised product quality across markets … across varied class of reactions Ability to handle complex chemistries.. High vacuum distillations • Cyclisation Grignard reaction Simple to
Slide 20: Complex Chemistries & Reaction (2/2)
Complex Chemistries & Reaction (2/2) SUPRIYA LIFESCIENCE LTD. Focus on uniform manufacturing standards to achieve standardised product quality across markets … across varied class of reactions Ability to handle complex chemistries.. Chiral molecules synthesis using Chiral auxiliary • Contrast media
Slide 21: Regulatory Achievements
Regulatory Achievements SUPRIYA LIFESCIENCE LTD. Strong focus on compliance guided by ethical approach • Our motto is to consistently meet the stringent requirements of regulatory bodies • Supported by a skilled team of regulatory affairs experts dedicated to the timely submission of dossiers and ma
Slide 22: Awards & Accreditation
Awards & Accreditation SUPRIYA LIFESCIENCE LTD . 2016 2017 2019 • Export House for the Year for 2015-16 awarded by • Export House for the Year for 2016-17 awarded by • Outstanding Export Performance Award for the year Directorate of Directorate of Industries, Government of Maharashtra 2018-19 for pr
Slide 23: Key Management Team
Key Management Team SUPRIYA LIFESCIENCE LTD. Satish Wagh Executive Chairman & WTD • An honorary Ph.D. in entrepreneurship from Faculty of Management Studies, National American University. • B.Sc. from R.D National College and W.A. Science College, University of Bombay. • Director on the board of Sup
Slide 24: EHS
EHS SUPRIYA LIFESCIENCE LTD. Environment Health Safety • Strict monitoring for high-efficiency pollution control; • Clean, safe and healthy working environment for our • Commitment to safe, accident-free operations across focus on solvent recovery and reduced emissions all employees facilities • Reg
Slide 25: CSR & Social Work
CSR & Social Work SUPRIYA LIFESCIENCE LTD. We believe true corporate citizenship is rooted in giving back to society, recognizing our responsibility extends beyond business paradigm • Regular activities hosted in the head office and factory for donations of utilities, clothes, school supplies from t
Slide 26: Historical Financial Performance
Historical Financial Performance SUPRIYA LIFESCIENCE LTD.
Slide 27: Consistent & Strong Financial Performance
Consistent & Strong Financial Performance SUPRIYA LIFESCIENCE LTD. (in INR Mn) Robust revenue growth Capex Spend … and, focus on profitability 12% 1,623 1,522 8,279 1,457 2,940 2,608 6,965 1,078 2,140 2,091 5,301 5,703 949 1,880 1,880 4,609 1,518 1,289 1,191 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 F
Slide 28: Working Capital Break-up
Working Capital Break-up SUPRIYA LIFESCIENCE LTD. (in days) Inventory Receivables 233 198 197 78 172 73 71 72 165 61 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 Payables Net Working Capital 113 112 105 235 196 158 170 59 124 49 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 27
Slide 29: Future Outlook
Future Outlook SUPRIYA LIFESCIENCE LTD.
Slide 30: Future Outlook
Future Outlook SUPRIYA LIFESCIENCE LTD. R&D centres CMO/CDMO space API R&D - • Evaluating opportunity for exclusive manufacturing rights in liquid inhalation products • Ambernath API R&D facility fully commissioned with a team of 16 scientists • GLP-1 portfolio development and supply in progress for
Slide 31: Thank You
e SUPRIYA LIFESCIENCE LTD. Supriya Lifescience Limited CIN: L51900MH2008PLC180452 Mr. Krishna Raghunathan - Chief Financial Officer cfo@supriyalifescience.com www.supriyalifescience.com EV Ernst & Young LLP Runjhun Jain Sneha Salian +91 98207 20993 +91 98194 30437 runjhun.jain1@in.ey.com sneha2.sali